<DOC>
	<DOCNO>NCT02438761</DOCNO>
	<brief_summary>Phase II open-label single-arm prospective multicentric clinical trial PF-05212384 ( PKI-587 ) deliver intravenous route . A 2-stage Fleming design employ .</brief_summary>
	<brief_title>PF-05212384 ( PKI-587 ) t-AML/MDS de Novo Relapsed Refractory Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>The treatment administer cycle 28 day period 4 cycle . Patients treat weekly basis continuously 112 day progression . Blood test ( hemogram ) assess weekly injection PF-05212384 ( PKI-587 ) . Bone marrow aspiration ( myelogram ) perform evaluate response start treatment start cycle 3 ( two cycle ) end study ( four cycle ) . Good responder continue treatment four cycle evaluate bone marrow aspiration ( myelogram ) every two cycle end treatment</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Patients belong one three category : Myeloid neoplasm secondary chemoradiotherapy ( tAML/MDS ) age 60 unfavorable cytogenetics ( European Leukemia Network definition 2010 ) , first cancer must remission two year , except situ carcinoma , basal cell carcinoma squamous cell carcinoma Relapsed refractory de novo AML age 18 ( multiple relapse allow ) , regardless risk group , provide eligible allogeneic bone marrow transplantation de novo AML diagnosis , age 60 consider unfit benefit induction chemotherapy associate aplasia ( discretion investigator ) 2 . Adequate glycemic balance define glycated hemoglobin ≤ 8 % 3 . Females childbearing potential ( FCBP ) receive effective contraception : negative pregnancy blood test require within 2 week start experimental treatment . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤ 2 5 . Absence severe active infection 6 . Adequate systolic cardiac function : Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % 7 . Adequate hepatic function : Aspartate Aminotransferase Test ( AST ) Alanine Aminotransferase Test ( ALT ) ≤ 3 time upper limit normal ( ULN ) , bilirubin ≤ 1.5 x ULN 8 . Adequate renal function : serum creatinine ≤ 1.5 x ULN calculate creatinine clearance &gt; 60 ml/min . 9 . Signed informed consent 1 . Glucose intolerance diabetes mellitus , treat untreated 2 . First cancer evolution ( solid tumor lymphoma ) remission less two year , except situ carcinoma , basal cell carcinoma squamous cell carcinoma 3 . AML secondary MDS myeloproliferative syndrome ( WHO 2008 definition ) 4 . Acute Promyelocytic Leukaemia ( APL AML French American British ( FAB ) classification 3 ) de novo secondary treatment ( tAPL ) 5. de novo secondary Core Binding Factor ( CBF ) /AML 6. de novo secondary Philadelphia Chromosome ( Ph ) 1 positive AML define presence ( 9.22 ) Breakpoint Cluster RegionAbelson Murine Leukemia Viral Oncogene Homolog ( BCRABL ) transcript 7 . Leukocytes 30.000/mm3 ( 30 G/L ) enrollment 8 . Antileukemic treatment within 15 day enrollment , exception hydroxyurea 9 . Central nervous system leukemic involvement 10 . Pregnant lactate woman , woman childbearing potential without effective contraception 11 . Prior history allogeneic bone marrow transplantation 12 . Prior history organ transplantation cause severe chronic immunodeficiency Human 13 . Seropositivity Human Immunodeficiency Virus ( HIV ) Human TLymphotropic Virus1 ( HTLV1 ) virus , active B C hepatitis 14 . Inclusion another experimental anticancer clinical trial* 15 . Patients unable undergo medical monitoring geographical , social psychological issue 16 . Patient measure legal protection 17 . No social security For ethical reason , exclusion period consider possibility participate another clinical study new experimental molecule determine , yet case discuss individual basis study coordinator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>PIK/Akt/mTor</keyword>
</DOC>